Latham & Watkins Advises SoftBank Vision Fund 2 in Ventus Therapeutics’ US$140 Series C Financing

Firm represents the lead investor in the financing that will help scale-up the biopharmaceutical company’s proprietary drug discovery platform.

February 23, 2022

Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, has announced the closing of a US$140 million Series C financing. The Series C is co-led by SoftBank Vision Fund 2 and RA Capital Management with participation from Qatar Investment Authority, Andreessen Horowitz, BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, Alexandria Venture Investments, GV (formerly Google Ventures), and founding investor Versant Ventures. 

Latham & Watkins LLP represents SoftBank Vision Fund 2 is the financing with a Bay Area-based emerging companies deal team led by partners Saad Khanani and Ben Potter, with associate Tulin Gurer. Advice was also provided on intellectual property matters by Bay Area partner Jekkie Kim and Los Angeles counsel Jia Jia Huang, with Boston associate Seth Appiah-Opoku.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.